Skip to main content
TipRanks
Go Ultimate75% OFF

Broncus Holding Corp. (2216) Stock Price & Analysis

0 Followers

2216 Stock Chart & Stats

HK$0.54-HK$0.01(-1.82%)
At close: 4:00 PM GMT+8
HK$0.6HK$0.7HK$0.8Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 0.53 - HKD 0.56
52-Week Range
HKD 0.53 - HKD 2.75
Previous Close
HKD 0.55
Volume
N/A
Average Volume (3M)
322.14K
Market Cap
HKD 285.52M
Enterprise Value
-HKD 503.14M
Total Cash (Recent Filing)
HKD 99.28M
Total Debt (Recent Filing)
HKD 244.97K
Price to Earnings (P/E)
―
Beta
1.67
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Extremely low leverage reduces refinancing pressure and preserves financial flexibility while the company works to stabilize operations. Positive equity provides a capital base that can support continued investment and absorb losses better than a highly indebted balance sheet.

Specialized Pulmonary Focus

A focused position in respiratory and pulmonary care gives Broncus a clearly defined clinical purpose and development platform. Concentration on minimally invasive bronchoscopic procedures may support deeper expertise and sustained relevance as physicians treat lung disease in specialized settings.

Historical Gross-Margin Capability

The history of solid gross margins indicates that the company has previously demonstrated an ability to generate value above product costs when commercial activity was healthier. Restoring revenue scale could therefore provide a foundation for margin recovery, although execution remains necessary.

Bears Say

Severe Revenue Deterioration

A revenue collapse of this magnitude signals a major loss of commercial traction and materially weakens operating leverage. Even with a specialized product focus, rebuilding demand and restoring a sustainable revenue base could take time, keeping earnings power highly uncertain.

Persistent Unprofitability

Repeated operating and net losses show that the business has not yet converted its technology and clinical focus into sustainable profitability. Negative gross profit in the latest year is especially concerning because it indicates pressure at the core product economics level, not just overhead.

Ongoing Cash Burn

Persistent negative operating and free cash flow means Broncus cannot currently self-fund its operations or growth from internally generated cash. Continued consumption of cash may require external financing and can constrain investment, particularly while revenue and margins remain weak.

Broncus Holding Corp. News

2216 FAQ

What was Broncus Holding Corp.’s price range in the past 12 months?
Broncus Holding Corp. lowest stock price was HK$0.53 and its highest was HK$2.75 in the past 12 months.
What is Broncus Holding Corp.’s market cap?
Broncus Holding Corp.’s market cap is HK$285.52M.
When is Broncus Holding Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Broncus Holding Corp.’s earnings last quarter?
Broncus Holding Corp. released its earnings results on Aug 27, 2026. The company reported -HK$0.157 earnings per share for the quarter.
Is Broncus Holding Corp. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Broncus Holding Corp. pay dividends?
Broncus Holding Corp. does not currently pay dividends.
What is Broncus Holding Corp.’s EPS estimate?
Broncus Holding Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Broncus Holding Corp. have?
Broncus Holding Corp. has 528,737,060 shares outstanding.
What happened to Broncus Holding Corp.’s price movement after its last earnings report?
Broncus Holding Corp. reported an EPS of -HK$0.157 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Broncus Holding Corp.?
Currently, no hedge funds are holding shares in HK:2216
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology